New drug combo aims to ease leg pain from clogged arteries
NCT ID NCT07600385
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tested whether adding cilostazol to rosuvastatin helps people with peripheral artery disease (PAD) more than rosuvastatin alone. PAD narrows leg arteries, causing pain and trouble walking. The study enrolled 260 adults who took either the combo or a placebo for 24 weeks. Researchers measured changes in walking ability and pain scores.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cilostazol and rosuvastatin combination
What this could lead to
If successful, this could offer a new treatment option to improve walking ability and reduce leg pain in people with peripheral artery disease.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The combination may not prove significantly better than rosuvastatin alone, and side effects from cilostazol (like headache or diarrhea) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University College of Medicine, Severance Hospital
Seoul, South Korea